CD19 and B-cell chronic lymphocytic leukemia: Of them, anti-CD19 CAR was expressed in hiPSCs together with a cleavable CD16 Fc receptor and an IL-15 receptor fusion prior to the induction of NK differentiation towards CAR-NK cells for the treatment of relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL) (NCT04245722) [180].